Jefferies reiterates Hold rating on Aurinia Pharmaceuticals stock at $10 price target
NeutralFinancial Markets

Jefferies has maintained a Hold rating on Aurinia Pharmaceuticals, setting a price target of $10 for the stock. This decision reflects the firm's cautious outlook on the company's performance, indicating that while there may be potential, investors should be mindful of the risks involved. This news is significant as it provides insight into the market's perception of Aurinia's future, which could influence investor decisions.
— Curated by the World Pulse Now AI Editorial System